Entering text into the input field will update the search result below

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2021 Results - Earnings Call Transcript

May 05, 2021 1:31 PM ETKALA BIO, Inc. (KALA)
SA Transcripts profile picture
SA Transcripts

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q1 2021 Earnings Conference Call May 5, 2021 8:00 AM ET

Company Participants

Niranjan Kameswaran - SVP, Strategy

Mark Iwicki - Chairman, President & CEO

Todd Bazemore - COO

Mary Reumuth - CFO & Treasurer

Conference Call Participants

Andreas Argyrides - Wedbush Securities

Christopher Neyor - JPMorgan Chase & Co.

François Brisebois - Oppenheimer

Tazeen Ahmad - Bank of America Merrill Lynch

Yi Chen - H.C. Wainwright & Co.

Timothy Chiang - Northland Capital Markets

Kelly Shi - Jefferies


Good morning and welcome to Kala Pharmaceuticals' First Quarter 2021 Financial Results Conference Call. [Operator Instructions]. As a reminder, this call is being recorded. I would now like to turn the call over to Niranjan Kameswaran, Senior Vice President of Strategy for Kala Pharmaceuticals. Please proceed.

Niranjan Kameswaran

Thank you, operator and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chairman, President and Chief Executive Officer; Todd Bazemore, Chief Operating Officer; Mary Reumuth, Chief Financial Officer; and Kim Brazzell, our Chief Medical Officer.

Today's call is being webcast live. The webcast link can be found in the Investors and Media section of our website at www.kalarx.com. During this call, we will be referring to non-GAAP financial measures, which are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in our press release issued today, which can also be found on our website.

On this call, we will make certain comments about Kala's future expectations, plans and prospects that are forward-looking statements within the meaning the Private Securities Litigation Reform Act of 1995. These statements will include statements regarding the potential market and commercial launch plans for EYSUVIS, observations associated with our commercialization of EYSUVIS and INVELTYS

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About KALA

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on KALA

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.